---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-205615"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:01:08.705680+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotech Q2 net loss $4.5M; THIO-101 Phase 2 DCR 82%, 35 patients enrolled

## Summary
- Cash $9.1M at June 30, 2023; net loss $4.5M for Q2 2023 vs $3.3M loss in Q2 2022.
- R&D expenses $2.6M, G&A $2.0M for the quarter.
- THIO-101 Phase 2: 35 patients dosed as of July 2023; preliminary DCR 82% (9 of 11 patients) at first assessment.
- First 2 patients alive without progression 10.2 and 8.5 months post-treatment, no additional therapy needed.
- Filed second provisional patent for third telomere-targeting molecule MAIA-2021-029.

## SEC filing metadata
- accession: 0001193125-23-205615
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/0001193125-23-205615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/d514056d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-205615
- JSON: https://secwatch.observer/filing/0001193125-23-205615.json
- Plain text: https://secwatch.observer/filing/0001193125-23-205615.txt

## Key facts
- Earnings Releases
  MAIA Biotechnology, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3
  - Result: reported results
  source text: MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/0001193125-23-205615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.